Showing papers by "James F. Fries published in 2010"
TL;DR: The first large-scale testing of PROMIS item banks and their short forms provide evidence that they are reliable and precise measures of generic symptoms and functional reports comparable to legacy instruments.
3,365Â citations
National Institutes of Health1, American College of Rheumatology2, Stanford University3, Mayo Clinic4, University of Colorado Hospital5, Cleveland Clinic6, University of Kentucky7, University of Illinois at Chicago8, Harvard University9, Johns Hopkins University10, SUNY Downstate Medical Center11, University of California, San Diego12
TL;DR: Criteria for the classification of Wegener's granulomatosis were developed by comparing 85 patients who had this disease with 722 control patients with other forms of vasculitis with a high level of sensitivity and specificity.
Abstract: Criteria for the classification of Wegener's granulomatosis (WG) were developed by comparing 85 patients who had this disease with 722 control patients with other forms of vasculitis. For the traditional format classification, 4 criteria were selected: abnormal urinary sediment (red cell casts or greater than 5 red blood cells per high power field), abnormal findings on chest radiograph (nodules, cavities, or fixed infiltrates), oral ulcers or nasal discharge, and granulomatous inflammation on biopsy. The presence of 2 or more of these 4 criteria was associated with a sensitivity of 88.2% and a specificity of 92.0%. A classification tree was also constructed with 5 criteria being selected. These criteria were the same as for the traditional format, but included hemoptysis. The classification tree was associated with a sensitivity of 87.1% and a specificity of 93.6%. We describe criteria which distinguish patients with WG from patients with other forms of vasculitis with a high level of sensitivity and specificity. This distinction is important because WG requires cyclophosphamide therapy, whereas many other forms of vasculitis can be treated with corticosteroids alone.
1,786Â citations
Mayo Clinic1, University of Colorado Hospital2, American College of Rheumatology3, Cleveland Clinic4, National Institutes of Health5, Stanford University6, University of Kentucky7, University of Illinois at Chicago8, Harvard University9, Johns Hopkins University10, SUNY Downstate Medical Center11, University of California, San Diego12
599Â citations
Stanford University1, American College of Rheumatology2, Mayo Clinic3, University of Colorado Hospital4, Cleveland Clinic5, National Institutes of Health6, University of Kentucky7, University of Illinois at Chicago8, Harvard University9, Johns Hopkins University10, SUNY Downstate Medical Center11, University of California, San Diego12
TL;DR: The Americal College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculopathy, Henoch-Schonlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis.
Abstract: The Americal College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculitis, Henoch-Schonlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis. The data collection methods, quality control, and analytic procedures used to derive the classification rules are discussed herein
575Â citations
American College of Rheumatology1, Cleveland Clinic2, Stanford University3, University of Colorado Hospital4, University of Calgary5, National Institutes of Health6, Mayo Clinic7, University of Kentucky8, University of Illinois at Chicago9, Harvard University10, Johns Hopkins University11, SUNY Downstate Medical Center12, University of California, San Diego13
TL;DR: Criteria for the classification of hypersensitivity vasculitis were developed by comparing 93 patients who had this disease with 714 control patients with other forms of vasculopathy, finding that the presence of 3 or more of these criteria was associated with a sensitivity of 71.0% and a specificity of 83.9%.
Abstract: Criteria for the classification of hypersensitivity vasculitis were developed by comparing 93 patients who had this disease with 714 control patients with other forms of vasculitis. For the traditional format classification, 5 criteria were selected: age greater than 16 at disease onset, history of taking a medication at onset that may have been a precipitating factor, the presence of palpable purpura, the presence of maculopapular rash, and a biopsy demonstrating granulocytes around an arteriole or venule. The presence of 3 or more of these 5 criteria was associated with a sensitivity of 71.0% and a specificity of 83.9%. A classification tree was also constructed. The criteria appearing in the tree structure were the same as for the traditional format, except there were 2 pathology criteria: one required the presence of granulocytes in the wall of an arteriole or venule, and the other required the presence of eosinophils in the inflammatory exudate. The classification tree was associated with a sensitivity of 78.5% and a specificity of 78.7%.
244Â citations
TL;DR: The American College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculopathy, Henoch-Schönlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis.
Abstract: The American College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculitis, Henoch-Schonlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis. The data collection methods, quality control, and analytic procedures used to derive the classification rules are discussed herein.
238Â citations
TL;DR: Overall toxicity Index scores were computed from symptoms, laboratory abnormalities, and hospitalizations attributed to nonsteroidal antiinflammatory drug (NSAID) therapy in 2,747 patients with rheumatoid arthritis, and these differences are both clinically and statistically significant.
Abstract: Toxicity Index scores were computed from symptoms, laboratory abnormalities, and hospitalizations attributed to nonsteroidal antiinflammatory drug (NSAID) therapy in 2,747 patients with rheumatoid arthritis receiving 5,642 courses of 11 NSAIDs over 8,481 patient-years. Substantial differences in overall toxicity were found, the differences between drugs often being clinically significant (2-3 times as toxic) and highly statistically significant. The results strengthened after adjustment for differing patient characteristics, held generally across multiple ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) data bank centers, and persisted after use of different techniques for the weighting of side effects. The most toxic side effects were experienced by patients taking indomethacin (mean +/- SEM score 3.99 +/- 0.58), tolmetin sodium (3.96 +/- 0.74), and meclofenamate sodium (3.86 +/- 0.66). Least toxic were coated or buffered aspirin (1.19 +/- 0.10), salsalate (1.28 +/- 0.34), and ibuprofen (1.94 +/- 0.43). The most toxic drugs were generally taken in the lowest relative doses. There are statistical differences in overall toxicity between different NSAIDs as used in rheumatoid arthritis, and these differences are both clinically and statistically significant.
142Â citations
TL;DR: A simple 3 x 3 table to rank both benefit and harm outcomes is feasible and will be further developed in the context of the OMERACT initiative.
26Â citations
4Â citations